Very Early Response to Sunitinib in VHL Patient with Pancreatic Neuroendocrine Tumor

#1550

Introduction: Pancreatic neuroendocrine tumors (pNET) arise in 8-17% of Von Hippel Lindau (VHL) patients and surgery plays a key role for resectable lesions. Alternative medical therapy, such as target therapy (TT), can be used when surgery is unfeasible

Aim(s): case report

Materials and methods: A 32 years old female affected by pNET in the spectrum of VHL presented a major nodule in the pancreatic body (62x71x45 mm) and similar lesions in the head (max 27 mm)

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Caff A

Authors: Caff A, Cittadini G, De Cian F, Sciallero S, Malandrino P,

Keywords: VHL therapy,